We serve Fmoc-Thr(tBu)-OL CAS:189337-28-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:9H-fluoren-9-ylmethyl N-[(2R,3R)-1-hydroxy-3-[(2-methylpropan-2-yl)oxy]butan-2-yl]carbamate
CAS.NO: 189337-28-8
Molecular Formula: C23H29NO4
Molecular Weight: 383.48100
Synonyms:
9H-Fluoren-9-ylmethyl {(2R,3R)-1-hydroxy-3-[(2-methyl-2-propanyl)oxy]-2-butanyl}carbamate
AmbotzFAL1034
Fmoc-Thr(tBu)-OL
Fmoc-Thr(t-Bu)-ol
9H-Fluoren-9-ylmethyl [(2R,3R)-3-tert-butoxy-1-hydroxybutan-2-yl]carbamate
Carbamic acid, N-[(1R,2R)-2-(1,1-dimethylethoxy)-1-(hydroxymethyl)propyl]-, 9H-fluoren-9-ylmethyl ester
(9H-Fluoren-9-yl)methyl ((2R,3R)-3-(tert-butoxy)-1-hydroxybutan-2-yl)carbamate
N-[(1R,2R)-2-(1,1-Dimethylethoxy)-1-(hydroxymethyl)propyl]carbamic acid 9H-fluoren-9-ylmethyl ester
(2R,3R)-2-(Fmoc-amino)-3-tert-butoxy-1-butanol
Physical and Chemical Properties:
Density: 1.145g / cm3
Boiling point: 576.497ºC at 760 mmHg
Flash point: 302.454ºC
Refractive index: 1.563
Specification:
Appearance: White powder
Purity:≥98%
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at 0ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.
Contact us for information like 9H-fluoren-9-ylmethyl N-[(2R,3R)-1-hydroxy-3-[(2-methylpropan-2-yl)oxy]butan-2-yl]carbamate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2R,3R)-2-(Fmoc-amino)-3-tert-butoxy-1-butanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Fmoc-Thr(tBu)-OL Use and application,Fmoc-Thr(tBu)-OL technical grade,usp/ep/jp grade.
Related News: The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.Ethanethiol manufacturer The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.1-Methylazepan-4-one supplier The company’s product reserves are rich, with more than one hundred varieties in various categories from intermediates to APIs. At present, the grays and anti-hepatitis C series intermediates are steadily advancing, which will ensure future growth.S-methyl thioacetate vendor The company’s product reserves are rich, with more than one hundred varieties in various categories from intermediates to APIs. At present, the grays and anti-hepatitis C series intermediates are steadily advancing, which will ensure future growth.In the TOP50 list of API export companies in 2017, the geographical clustering of advantageous companies is still obvious. For example, Huahai and Pluo in Zhejiang, CSPC of Hebei, Xinhua Pharmaceutical and Xinfa Pharmaceutical of Shandong rank well. Rank.
